5-amino-1mq peptide benefits may include fat loss, better glucose control, and NAD+ support. Here's what the research actually shows, plus safety and dosing.
5-amino-1MQ is a synthetic research compound that blocks an enzyme called nicotinamide N-methyltransferase (NNMT), and the benefits most often discussed are reduced body fat, better glucose tolerance, and higher cellular NAD+ levels. Nearly all of that evidence comes from studies in mice, not human clinical trials. 5-amino-1MQ is not FDA-approved for human use and is sold only as a research chemical.
What Is 5-Amino-1MQ?
5-amino-1MQ, short for 5-amino-1-methylquinolinium, is a quinolinium salt described in the scientific literature as a potent, cell-permeable NNMT inhibitor. It is small, stable, and orally active in animal models, which is one reason it gets so much attention in online fitness circles.
The compound is often searched as a 5-amino-1mq peptide, but that label is technically inaccurate. A true peptide is a short chain of amino acids, while 5-amino-1MQ is a single small molecule. The confusion likely comes from the fact that it is sold by the same vendors that stock BPC-157, TB-500, and similar research compounds.
How 5-Amino-1MQ Works
NNMT consumes nicotinamide and S-adenosylmethionine, two molecules cells need for energy metabolism and methylation. When NNMT is overactive, as it often is in the fat tissue of people with obesity, it drains those resources and pushes adipose tissue toward storing fat rather than burning it.
By inhibiting NNMT, 5-amino-1MQ appears to raise available NAD+ and SAM while limiting fat-cell expansion. In mice, this happens without a drop in food intake, which suggests the effect comes from metabolism rather than appetite suppression.
Potential Benefits Reported in Research
Body fat and weight loss
In a widely cited animal study, obese mice treated with 5-amino-1MQ lost significant body weight and fat mass, and their fat cells were measurably smaller. Treated mice also showed less fat accumulation in the liver.
These results are promising but preliminary. A mouse study is not proof that a compound will produce the same 5-amino-1mq benefits in humans, and no human trial has tested this compound for weight loss.
Blood sugar and metabolic markers
Researchers have reported improved glucose tolerance and insulin sensitivity in treated animals, along with lower circulating lipids. That pattern is consistent with what you would expect from a compound that blocks NNMT activity in fat tissue.
Metabolic improvements in mice do not automatically translate into better blood sugar in people. Anyone with diabetes or prediabetes should treat these findings as early science, not as a treatment plan.
NAD+ and cellular energy
Because NNMT consumes nicotinamide, inhibiting it may indirectly support NAD+, a coenzyme involved in energy production and DNA repair. NAD+ levels decline with age, which is why so many longevity products are marketed around raising it.
Whether 5-amino-1MQ meaningfully raises NAD+ in human tissue is unknown. No published human study has measured that.
How 5-Amino-1MQ Compares to Other Metabolic Research Compounds
People researching metabolic compounds usually compare several options at once, and the table below shows how 5-amino-1MQ stacks up against other popular agents.
| Compound | Primary Mechanism | Best Available Evidence | Main Limitation |
|---|---|---|---|
| 5-Amino-1MQ | NNMT inhibition, raises NAD+ | Mouse studies: fat loss, better glucose tolerance | No human trials |
| AOD-9604 | Modified HGH fragment with lipolytic activity | Small human studies with mixed results | Modest, inconsistent effects |
| CJC-1295 + Ipamorelin | Growth hormone secretagogues | Human data on GH and IGF-1 levels | Not direct fat-loss endpoints |
| DSIP | Sleep-related neuropeptide | Small, older studies on sleep quality | Very limited modern research |
| SS-31 (Elamipretide) | Binds cardiolipin in mitochondria | Human trials in rare mitochondrial disease | Not a fat-loss compound |
Anyone weighing peptide aod 9604 benefits against 5-amino-1MQ should note that AOD-9604 is a modified fragment of human growth hormone studied for fat metabolism, while 5-amino-1MQ acts through a completely different enzyme pathway. Growth hormone secretagogues are a separate category again, and most people digging into cjc-1295 ipamorelin peptide benefits are chasing body-composition changes rather than direct NNMT inhibition.
Dosage, Legal Status, and Human Data Gaps
There is no established human dose of 5-amino-1MQ. Online sources commonly mention 50 mg to 150 mg per day taken orally, but those numbers are anecdotal and are not supported by clinical research.
In the United States, 5-amino-1MQ is not an approved drug, and it is not a permitted dietary supplement ingredient. Vendors sell it with 'not for human consumption' labels, which means quality, purity, and actual content can vary widely between suppliers.
- No human trials have reported safety or efficacy.
- No standard dose, dosing schedule, or delivery form has been validated.
- Product purity is not guaranteed by any regulator.
Side Effects and Safety Considerations
Side effects reported in user anecdotes include nausea, stomach discomfort, headaches, and fatigue. Because there is no human safety data, the real risk profile of 5-amino-1MQ is unknown.
NNMT is not only a fat enzyme. It is active in the liver and has been studied in cancer biology, so blocking it for months or years could have consequences nobody has mapped yet. Anyone reviewing 5-amino-1mq benefits and side effects should weigh how thin the safety evidence is against the marketing claims.
Talk with a healthcare professional before using any unapproved research compound, especially if you take prescription medication, are pregnant or breastfeeding, or have a liver or metabolic condition.
The bottom line: 5-amino-1MQ is an interesting NNMT inhibitor with strong mouse data on fat loss and glucose metabolism, but it has no human trials, no approved dose, and no verified safety record. It is a research chemical, not a proven fat-loss solution, and claims about its benefits should be read with that gap in mind.
Frequently Asked Questions
Does 5-amino-1MQ actually help with fat loss?
In obese mice, 5-amino-1MQ reduced body weight and fat mass without changing food intake, and it improved glucose tolerance. No human trial has tested it for fat loss, so there is no proof it produces the same effect in people. Any human fat-loss claim is currently an extrapolation from animal data.
Is 5-amino-1MQ FDA-approved or legal to buy?
No. 5-amino-1MQ is not FDA-approved for any human use, and it is not a permitted dietary supplement ingredient in the United States. It is sold as a research chemical with a 'not for human consumption' label, which means purity and dosing are unregulated.
What side effects are reported with 5-amino-1MQ?
User reports mention nausea, stomach upset, headaches, and fatigue, but no clinical trial has systematically tracked side effects. The long-term effects of inhibiting NNMT are unknown. Anyone considering it should consult a healthcare professional first.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.